http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100470535-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate | 2002-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100470535-B1 |
| titleOfInvention | Immunoliposome conjugated with upa antibody |
| abstract | The present invention relates to a selective drug delivery tool that targets cells expressing abundant urokinase type plasminogen activator (uPA) such as cancer cells or neovascular endothelial cells in cancer tissues. In addition to the cancer cell self-killing effect, when an anti-cancer agent is included inside an immunooliposome attached to an anti-uPA monoclonal antibody produced by a fusion cell of a splenic lymphocyte and myeloma cells In addition, by killing vascular endothelial cells to block the formation of neovascularization, the secondary effect of inducing cancer tissue necrosis can also be obtained. |
| priorityDate | 2002-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.